Rosuvastatin/valsartan - LG Chem

Drug Profile

Rosuvastatin/valsartan - LG Chem

Alternative Names: Rovatitan; Valsartan/rosuvastatin; VR

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; Merck Ltd. Korea
  • Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 31 Mar 2013 LG Life Sciences completes a phase III trial in Hypertension & hyperlipidaemia in South Korea (NCT01918332)
  • 31 Jan 2013 LG Life Sciences completes a phase I bioequivalence trial for Hypertension & hyperlipidaemia (in volunteers) in South Korea (NCT01918358)
  • 31 Dec 2012 LG Life Sciences initiates enrolment in a phase I bioequivalence trial for Hypertension & hyperlipidaemia (in volunteers) in South Korea (NCT01918358)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top